Tandem Diabetes Care, Inc. (TNDM) Stock Price

TNDMStock

$21.58+86.25%52W

Market Cap$1.50B

P/E—

PEG Ratio—

Div yield—

Beta1.62

TNDM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)6.07%

Price vs S&P 500 (4W)22.06%

VGM Score51.30

Book Value / Share (Quarterly)$1.88

P/TBV (Annual)10.39x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)8.19%

Cash Flow / Share (Quarterly)$-1.55

Price vs S&P 500 (YTD)-10.87%

Gross Margin (TTM)56.01%

Net Profit Margin (TTM)-6.08%

EPS (TTM)$-0.93

10-Day Avg Trading Volume1.68M

EPS Excl Extra (TTM)$-0.93

Revenue Growth (5Y)15.26%

EPS (Annual)$-3.04

ROI (Annual)-43.55%

Gross Margin (Annual)53.81%

Net Profit Margin (5Y Avg)-13.95%

Cash / Share (Quarterly)$6.56

Revenue Growth QoQ (YoY)5.77%

ROA (Last FY)-23.23%

Revenue Growth TTM (YoY)3.96%

EBITD / Share (TTM)$-0.41

ROE (5Y Avg)-51.46%

Operating Margin (TTM)-4.40%

Cash Flow / Share (Annual)$-0.43

P/B Ratio12.34x

P/B Ratio (Quarterly)7.93x

Net Income / Employee (Annual)$-81,900

EV / Revenue (TTM)2.07x

Net Interest Coverage (TTM)-14.39x

ROA (TTM)-6.23%

EV / EBITDA (TTM)307.72x

EPS Incl Extra (Annual)$-3.04

Current Ratio (Annual)2.55x

Quick Ratio (Quarterly)2.44x

3-Month Avg Trading Volume2.29M

52-Week Price Return86.25%

Revenue / Employee (TTM)$416,600

Tangible BV / Share (Quarterly)$2.10

P/S Ratio (Annual)1.59x

Asset Turnover (Annual)1.15x

52-Week High$29.65

Operating Margin (5Y Avg)-13.73%

EPS Excl Extra (Annual)$-3.04

CapEx CAGR (5Y)-9.19%

Tangible BV CAGR (5Y)-16.69%

26-Week Price Return17.32%

Quick Ratio (Annual)1.89x

13-Week Price Return40.99%

Total Debt / Equity (Annual)2.03x

Current Ratio (Quarterly)3.18x

Enterprise Value$2.15B

Revenue / Share Growth (5Y)13.02%

Asset Turnover (TTM)1.03x

Book Value / Share Growth (5Y)-17.32%

Revenue / Employee (Annual)$405,900

Inventory Turnover (Annual)3.37x

Pretax Margin (Annual)-19.74%

Cash / Share (Annual)$4.29

3-Month Return Std Dev75.80%

Gross Margin (5Y Avg)52.03%

Net Income / Employee (TTM)$-25,300

EBITDA Interim CAGR (5Y)-10.36%

ROE (Last FY)-131.93%

Net Interest Coverage (Annual)-3.01x

EPS Basic Excl Extra (Annual)$-3.04

P/FCF (TTM)133.42x

Receivables Turnover (TTM)7.17x

Total Debt / Equity (Quarterly)4.66x

EPS Incl Extra (TTM)$-0.93

Receivables Turnover (Annual)7.25x

ROI (TTM)-10.58%

P/S Ratio (TTM)1.55x

Pretax Margin (5Y Avg)-13.66%

Revenue / Share (Annual)$15.08

Tangible BV / Share (Annual)$2.10

Price vs S&P 500 (52W)67.94%

Year-to-Date Return1.09%

5-Day Price Return-6.36%

EPS Normalized (Annual)$-3.04

ROA (5Y Avg)-12.76%

Net Profit Margin (Annual)-20.17%

Month-to-Date Return13.95%

Cash Flow / Share (TTM)$-2.98

EBITD / Share (Annual)$-2.52

Operating Margin (Annual)-18.45%

LT Debt / Equity (Annual)2.03x

P/CF (TTM)78.21x

ROI (5Y Avg)-21.38%

LT Debt / Equity (Quarterly)4.66x

EPS Basic Excl Extra (TTM)$-0.93

P/TBV (Quarterly)10.39x

P/B Ratio (Annual)9.60x

Inventory Turnover (TTM)3.30x

Pretax Margin (TTM)-5.86%

Book Value / Share (Annual)$2.27

Price vs S&P 500 (13W)38.20%

Beta1.62x

P/FCF (Annual)214.58x

Revenue / Share (TTM)$15.09

ROE (TTM)-45.97%

52-Week Low$11.16

vGradeD

gGradeC

mGradeB

vgmGradeC

TNDM Earnings Surprise History

Q2 25-0.48est. -0.40

Q3 25-0.31est. -0.34

Q4 25-0.01est. -0.09

Q1 26-0.30est. -0.44

Q2 26-0.31est. -0.32

TNDM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.79

3.82

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.58
SYKStryker Corporation	C	B	C	$330.59
MMM3M Company	C	D	B	$179.37
BSXBoston Scientific Corp.	C	B	D	$49.86
BDXBecton, Dickinson and Co.	B	D	B	$189.78
MDLNMedline Inc. Class A common stock	C	D	C	$35.64
RMDResMed Inc.	C	B	C	$236.59
DXCMDexCom, Inc.	D	B	B	$89.16
WSTWest Pharmaceutical Services, Inc.	D	C	B	$348.48
SOLVSolventum Corporation	C	C	B	$91.61
BAXBaxter International Inc.	B	D	B	$26.29
PENPenumbra, Inc.	D	C	C	$324.37
GMEDGLOBUS MEDICAL INC	B	B	C	$82.96
GKOSGlaukos Corporation	F	A	A	$181.39
PODDInsulet Corporation	C	A	D	$143.05
STVNStevanato Group S.p.A.	D	C	B	$22.70
TFXTeleflex Incorporated	B	F	B	$140.18
MMSIMerit Medical Systems Inc	C	B	B	$91.09
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$18.92
HAEHaemonetics Corporation	C	C	A	$108.32
ICUIICU Medical Inc	C	D	B	$182.24
HTFLHeartflow, Inc. Common Stock	—	A	A	$49.89
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$123.09
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$49.00
ATRCAtriCure, Inc.	D	B	A	$48.68
UFPTUFP Technologies Inc	C	B	B	$304.21
NVCRNovoCure Limited Ordinary Shares	D	C	C	$17.62
LMATLeMaitre Vascular, Inc.	C	B	D	$78.97
INSPInspire Medical Systems, Inc.	B	B	B	$61.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$26.92
ATECAlphatec Holdings, Inc.	D	B	C	$9.33
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.70
IARTIntegra LifeSciences Holdings	B	D	C	$16.79
AORTArtivion, Inc.	C	C	C	$26.38
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$21.60
IRMDiRadimed Corporation	D	B	C	$87.87
BVSBioventus Inc. Class A Common Stock	B	C	A	$14.08
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.60
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.54
BBNXBeta Bionics, Inc. Common Stock	D	A	A	$19.34
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.55
ANGOAngioDynamics, Inc.	C	D	B	$15.95
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$24.50
MDXGMiMedx Group, Inc	C	D	C	$4.34
DCTHDelcath Systems Inc	D	B	A	$16.92
BWAYBrainsway Ltd. American Depositary Shares	F	A	C	$14.43
CERSCerus Corp	D	C	B	$2.72
TCMDTactile Systems Technology, Inc.	B	B	C	$23.58
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$16.96
NPCENeuropace, Inc. Common Stock	D	C	C	$14.16
SIShoulder Innovations, Inc.	—	B	A	$22.32

About Tandem Diabetes Care, Inc.

Tandem Diabetes designs and manufactures insulin pumps and related disposables for diabetes management. Since entering the market in 2012, the company has built a portfolio including its flagship t:slim X2 device and recently launched Mobi pump, with tubeless options (Tobi and Sigi) in development. Pumps account for approximately half of revenue, with disposable infusion sets representing one-third of sales. The company derives roughly 75% of revenue from the US market, with the remainder from other developed nations.